Study Examines Prescription Rates for Rituximab Biosimilars in European NHL Patients
News
European patients with non-Hodgkin’s lymphoma (NHL) are more likely to receive rituximab biosimilars if they are fitter, have indolent disease, or follicular lymphoma, according to a new study. The study, “Treatment approach for ... Read more